First, what is tirzepatide? What physical changes can be expected after taking it?
Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. By mimicking two natural hormones in the body, it promotes insulin secretion and inhibits glucagon release in a glucose-dependent manner, while also slowing gastric emptying and suppressing appetite, thereby lowering blood glucose levels and promoting weight loss.
Key Clinical Benefits
· Potent Weight Loss: In obese adults without diabetes, tirzepatide demonstrates significant weight loss. A head-to-head study showed that after 72 weeks of treatment, the tirzepatide group experienced an average weight loss of 20.2%, compared to 13.7% in the semaglutide group. A Cochrane systematic review also confirmed that it effectively reduces weight in the medium term (up to 2 years), and the effects may be sustained long-term.
· Improved Glycemic Control: As its initially approved indication, tirzepatide effectively improves blood glucose levels in patients with type 2 diabetes. FDA data indicate that it enhances insulin sensitivity and reduces glucagon levels.
· Cardiovascular and renal benefits: Long-term studies suggest that tirzepatide may reduce the risk of major adverse cardiovascular events and have a beneficial effect on renal outcomes. Additionally, it has been approved to improve symptoms of obstructive sleep apnea (OSA) in obese patients.
· Improved body composition: Current evidence indicates that, while promoting weight loss, tirzepatide preferentially reduces metabolically harmful fat while relatively preserving muscle mass. A study comparing various GLP-1 agonists showed that with an average weight loss of 9.9%, fat mass decreased by 18%, while skeletal muscle mass decreased by only 5%.
Major Risks and Adverse Reactions
· Gastrointestinal Reactions: These are the most common adverse reactions and are dose-dependent, primarily including nausea, vomiting, diarrhea, and constipation. At higher doses, symptoms such as indigestion and belching may be more pronounced.
· Serious Risk Warnings:
· Thyroid C-cell tumors: Animal studies have shown that tirzepatide can cause thyroid C-cell tumors. Therefore, this medication is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma or those with type 2 multiple endocrine neoplasia syndrome.
· Pancreatitis and Gallbladder Disease: The prescribing information indicates a potential risk of pancreatitis; however, a 2026 meta-analysis concluded that, compared to placebo, there was no significant increase in the risk of gallbladder disease or pancreatitis.
· Hypoglycemia: The risk of hypoglycemia increases when used in combination with insulin or sulfonylureas.
· Other Concerns:
· Weight Rebound After Discontinuation: Weight may increase again after discontinuation, indicating the need for long-term, continuous treatment.
· Muscle Loss: Although muscle mass is relatively well-preserved, rapid weight loss may still be accompanied by a decrease in muscle mass; attention to nutritional intake is required.
· Long-Term Safety Unknown: The longest trial lasted only about 2 years; long-term tolerability and long-term safety (such as tumor-related endpoints) remain unclear.